Digirad Co. (NASDAQ:DRAD)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $5.81. Digirad shares last traded at $5.78, with a volume of 73 shares traded.
Separately, ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd.
The business has a fifty day moving average price of $5.15. The company has a current ratio of 1.59, a quick ratio of 1.18 and a debt-to-equity ratio of 0.62.
In related news, Director Jeffrey E. Eberwein acquired 85,000 shares of the firm’s stock in a transaction on Wednesday, May 8th. The shares were purchased at an average price of $0.66 per share, with a total value of $56,100.00. Following the acquisition, the director now directly owns 644,152 shares in the company, valued at $425,140.32. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders have acquired 158,538 shares of company stock worth $103,800. Insiders own 7.30% of the company’s stock.
An institutional investor recently bought a new position in Digirad stock. Weber Alan W bought a new position in Digirad Co. (NASDAQ:DRAD) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 100,000 shares of the medical equipment provider’s stock, valued at approximately $91,000. Weber Alan W owned about 0.49% of Digirad as of its most recent filing with the Securities and Exchange Commission.
Digirad Company Profile (NASDAQ:DRAD)
Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through three segments: Diagnostic Services, Mobile Healthcare, and Diagnostic Imaging. The Diagnostic Services segment provides nuclear and ultrasound imaging services to physicians who perform nuclear imaging, echocardiography, vascular or general ultrasound tests, imaging systems, radiopharmaceuticals, and licensing services.
Featured Article: What are economic reports?
Receive News & Ratings for Digirad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad and related companies with MarketBeat.com's FREE daily email newsletter.